* Express Scripts says it has raised generic drug utilization to 47% during the first quarter of 2003. The PBM has been aggressively promoting generic versions of Prozac, Glucophage, Zestril, Prinivil and Zestoretic/ Prinzide. Efforts in the coming year will include ACE inhibitors Accupril and Monopril, and in 2004 Cipro and Celexa are scheduled for patent expirations. Express Scripts CEO Barrett Toan stated that the money-saving opportunities associated with generics will continue to grow over the next five years, when patents on brandname drugs representing $32.3 billion in sales will expire. This is equivalent to 16.8% of 2002 U.S. prescription sales. Express Scripts says the primary tools for encouraging generic utilization are copay incentives and member education. The PBM also reports that more clients are implementing step-therapy programs, and it now offers a special "low-cost" formulary to guide members toward generics. Another initiative includes co-branding educational materials with the FDA. Information: Steve Littlejohn, Express Scripts, (314) 702-7556, firstname.lastname@example.org.
COPYRIGHT 2003 Atlantic Information Services, Inc.
COPYRIGHT 2003 Gale Group